CPSE:VELO

Stock Analysis Report

Executive Summary

Veloxis Pharmaceuticals A/S, a specialty pharmaceutical company, engages in enhancing the lives of transplant patients by identifying, developing, and commercializing products in transplantation.

Snowflake

Fundamentals

High growth potential with acceptable track record.

Risks

  • Veloxis Pharmaceuticals has significant price volatility in the past 3 months.
  • Veloxis Pharmaceuticals is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Veloxis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.1%

CPSE:VELO

0.6%

DK Pharmaceuticals

-0.5%

DK Market


1 Year Return

271.6%

CPSE:VELO

8.6%

DK Pharmaceuticals

6.8%

DK Market

VELO outperformed the Pharmaceuticals industry which returned 8.3% over the past year.

VELO outperformed the Market in Denmark which returned 6.8% over the past year.


Share holder returns

VELOIndustryMarket
7 Day0.1%0.6%-0.5%
30 Day4.7%-0.08%0.5%
90 Day69.6%1.1%0.6%
1 Year271.6%271.6%14.6%8.6%10.1%6.8%
3 Year205.6%205.6%24.1%10.2%31.2%20.3%
5 Year90.5%90.5%24.8%4.3%64.4%40.4%

Price Volatility Vs. Market

How volatile is Veloxis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Veloxis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Veloxis Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Veloxis Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Veloxis Pharmaceuticals is overvalued based on earnings compared to the Europe Pharmaceuticals industry average.

Veloxis Pharmaceuticals is overvalued based on earnings compared to the Denmark market.


Price Based on Expected Growth

Veloxis Pharmaceuticals is poor value based on expected growth next year.


Price Based on Value of Assets

Veloxis Pharmaceuticals is overvalued based on assets compared to the Europe Pharmaceuticals industry average.


Next Steps

Future Growth

How is Veloxis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

79.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Veloxis Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Veloxis Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Veloxis Pharmaceuticals's revenue growth is expected to exceed the Denmark market average.

Veloxis Pharmaceuticals's earnings growth is expected to exceed the Denmark market average.

Veloxis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Veloxis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Veloxis Pharmaceuticals performed over the past 5 years?

24.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Veloxis Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.

Veloxis Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Veloxis Pharmaceuticals has become profitable in the last year making it difficult to compare the Europe Pharmaceuticals industry average.


Return on Equity

Whilst Veloxis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.


Return on Assets

Veloxis Pharmaceuticals used its assets more efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Veloxis Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Veloxis Pharmaceuticals's financial position?


Financial Position Analysis

Veloxis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Veloxis Pharmaceuticals's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Veloxis Pharmaceuticals's level of debt (562.3%) compared to net worth is high (greater than 40%).

Unable to establish if Veloxis Pharmaceuticals's debt level has increased without past 5-year debt data.

Operating cash flow is negative therefore debt is not well covered.

Interest payments on debt are not well covered by earnings (EBIT is 0.3x annual interest expense, ideally 3x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.9x debt.


Next Steps

Dividend

What is Veloxis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Veloxis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Veloxis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Veloxis Pharmaceuticals has not reported any payouts.

Unable to verify if Veloxis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Veloxis Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Veloxis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Craig Collard (53yo)

3.8yrs

Tenure

0

Mr. Craig Alexander Collard is an Independent Director at TerrAscend Corp. since December 6, 2018. He has been Independent Director of Opiant Pharmaceuticals, Inc. since October 29, 2018. He has been the C ...


Management Age and Tenure

1.0yrs

Average Tenure

The average tenure for the Veloxis Pharmaceuticals management team is less than 2 years, this suggests a new team.


Board Age and Tenure

12.3yrs

Average Tenure

55yo

Average Age

The average tenure for the Veloxis Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Craig Collard (53yo)

    President & CEO

    • Tenure: 3.8yrs
  • Ira Duarte

    Chief Financial Officer

    • Tenure: 1yrs
  • Mark Hensley

    Chief Commercial Officer

    • Tenure: 0.7yrs

Board Members

  • Paul Wotton (59yo)

    Independent Director

    • Tenure: 3.2yrs
  • Mette Agger (55yo)

    Deputy Chairman

    • Tenure: 3.4yrs
  • Mike Heffernan (55yo)

    Chairman of the Board

    • Tenure: 3.4yrs
  • Anders Götzsche (52yo)

    Independent Director

    • Tenure: 11.4yrs
  • Marc Pescovitz

    Member of Transplant Scientific Advisory Board

    • Tenure: 12.3yrs
  • John Lake

    Member of Transplant Scientific Advisory Board

    • Tenure: 12.3yrs
  • Josep M. Grinyó

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Robert Gaston

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Klemens Budde

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Rita Alloway

    Member of Transplant Scientific Advisory Board

    • Tenure: 12.3yrs

Company Information

Veloxis Pharmaceuticals A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Veloxis Pharmaceuticals A/S
  • Ticker: VELO
  • Exchange: CPSE
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø6.588b
  • Shares outstanding: 1.74b
  • Website: https://www.veloxis.com

Number of Employees


Location

  • Veloxis Pharmaceuticals A/S
  • Amerika Plads 37
  • Copenhagen
  • Capital Region of Denmark
  • 2100
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VELOCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKNov 2006
L8HDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2006
0IVILSE (London Stock Exchange)YesOrdinary SharesGBDKKNov 2006
LFCY.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2006

Biography

Veloxis Pharmaceuticals A/S, a specialty pharmaceutical company, engages in enhancing the lives of transplant patients by identifying, developing, and commercializing products in transplantation. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 20:54
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.